HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of neo-adjuvant chemotherapy with TEC regimen on breast cancer.

AbstractOBJECTIVE:
This study aims to investigate the efficacy of neo-adjuvant chemotherapy with TEC regimen (taxotere-epirubicin-cyclophosphamide) in the treatment of breast cancer (BC) patients.
METHOD:
Total of 118 BC patients were recruited from the Department of Breast Surgery in Shengjing Hospital of China Medical University from January 1, 2010 to December 31, 2012, in this study. The clinical data and serum samples were collected from each patient prior to the study. All patients were given four cycles of TEC chemotherapy before surgery.
RESULTS:
The overall response rate of TEC regimen in the treatment of BC was 67.8% (80/118), clinical complete response rate was 3.4% (4/118), and clinical partial response rate was 64.4% (76/118). Furthermore, we found that age, tumor size, lymph node metastasis and clinical stages of patients had no statistically significant difference (all P > 0.05). Both negative ER status and negative PR status were statistically related to better response (P = 0.033 and P = 0.024, respectively) when compared with the positive ER status and positive PR status, while such association was not observed between the negative HER-2 status and positive HER-2 status (P > 0.05). In addition, the efficacy of triple-negative breast cancer was significantly better than that of luminal A, luminal B and HER-2+ cancers (all P < 0.05), but there was no significant difference among the HER-2+, luminal A, luminal B groups (all P > 0.05).
CONCLUSION:
Our study support the view that BC cases under the TEC chemotherapy were related to higher overall response rates; and the chemotherapy with the TEC regimen could be served as an effective therapy in the treatment of BC.
AuthorsXi Gu, Yang Zhang, Long Chen, Jiao Guo, Wen-Hai Zhang
JournalCancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 75 Issue 2 Pg. 301-8 (Feb 2015) ISSN: 1432-0843 [Electronic] Germany
PMID25480315 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers, Tumor
  • Taxoids
  • Etoposide
  • Cyclophosphamide
  • ERBB2 protein, human
  • Receptor, ErbB-2
Topics
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Biomarkers, Tumor (genetics, metabolism)
  • Breast Neoplasms (drug therapy, pathology)
  • Cyclophosphamide (therapeutic use)
  • Etoposide (therapeutic use)
  • Female
  • Humans
  • Middle Aged
  • Neoadjuvant Therapy (methods)
  • Neoplasm Metastasis
  • Receptor, ErbB-2 (genetics, metabolism)
  • Taxoids (therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: